RDEA806: Phase IIb start

Next quarter, Ardea will begin an active-controlled, international Phase IIb trial in about 300 patients to compare 3 dose regimens of RDEA806 vs. Sustiva efavirenz from Bristol-Myers Squibb Co. (NY...